Using anti‐Aβ antibodies to modulate the multi‐pronged human microglia response to Aβ pathology
Overall, we provide the first evidence that microglia are crucial for the efficacy of anti-Aβ immunotherapy and provide real insight into the working mechanisms of this first disease-modifying therapy for AD.
Authors
- Tom Jaspers (ORCID: https://orcid.org/0000-0002-7485-4397)
- Giulia Albertini (ORCID: https://orcid.org/0000-0002-8215-2432)
- Bart De Strooper (ORCID: https://orcid.org/0000-0001-5455-5819)
- Marie‐Lynn Cuypers (ORCID: https://orcid.org/0000-0001-7540-389X)
- Maarten Dewilde (ORCID: https://orcid.org/0000-0002-3138-281X)
- Leen Wolfs (ORCID: https://orcid.org/0009-0003-5193-6722)
- Mark Fiers (ORCID: https://orcid.org/0000-0001-5694-2409)
- Emanuela Pasciuto (ORCID: https://orcid.org/0000-0002-5391-9585)
- Katrien Horré (ORCID: https://orcid.org/0000-0002-6801-3137)
- Magdalena Zielonka (ORCID: https://orcid.org/0000-0001-9641-9778)
- Katleen Craessaerts (ORCID: https://orcid.org/0000-0001-6684-8475)
- Veerle van Lieshout (ORCID: https://orcid.org/0000-0003-4033-4286)
- An Snellinx
Institutions
- University of Antwerp (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- UK Dementia Research Institute (GB)
- University College London (GB)
- KU Leuven (BE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/alz.087213
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00